Skip to main content

Table 1 Clinical profile of patients followed at start of study

From: Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study

Pt

Age (yrs)

Wt (kg)

FEV1 (%)

% HbA1c at Dx

Rx Course (yrs)

Clinical Data

I1

28

65.8

56

5.5

4

PI, LupusN, Deceased

I2

31

65.3

44

14.3

2

PI, Deceased

I3

13

41.9

57

9.3

4

PS

I4

33

54.3

18

10.0

2

PI, Deceased, RI*

I5

14

49.0

99

10.9

8

PI

I6

44

81.5

30

9.2

5

PI, Cor P, HTN, BPH

I7

24

53.0

57

7.3

3

PI, AIHS, RI

I8

21

70.5

93

9.8

10

PI

S1

29

75.5

71

7.1

1

PI

S2

17

33.6

33

8.1

2

PI, Deceased

S3

25

73.9

48

7.8

4

PI, Deceased

S4

33

97.5

83

6.3

1

PI, Bipolar, HTN

S5

18

49.7

30

6.6

1

PI, Deceased

M1I4

35

51.5

17

9.7

1

PI

M2

24

71.1

117

5.4

2

PI

M3I5

22

68.5

68

9.6

2

PI

M4

19

70.0

100

6.1

3

PI

M5

22

67.7

88

13.3

3

PI, Hepatic Cirrhosis

M6

15

41.8

85

8.9

5

PI

T1

29

58.0

47

13.3

2

PI

T2

20

44.4

23

5.1

1

PI

T3I6

49

85.5

29

9.2

2

PI, Cor P, HTN, BPH

T4I7

32

55.7

65

7.3

2

PI, AIHS, RI

T5S4

34

96.5

92

6.3

1

PI, Bipolar, HTN

T6

40

54.0

56

9.6

2

PI, Lupus, RI ABPA

  1. Pt, patient (subscripts identify patient number, e.g. M1I4 was the first patient started on metformin and the fourth patient started on insulin); Rx Course (Yrs), represents the number of years that a patient received consecutive therapy with a specific class of agent; Mon, months; I, insulin; S, sulfonylurea; M, metformin; T, thiazolidinediones, FEV1, forced expiratory volume at 1 second; HbA1c, percent glycosylated hemoglobin; PI, pancreatic insufficient; PS, pancreatic sufficient; LupusN, lupus with nephritis; RI, renal insufficiency; Cor P, cor pulmonale; HTN, hypertension; BPH, benign prostatic hypertrophy; AIHS, autoimmune hypersplenism; ABPS, allergic bronchopulmonary aspergillosis. *Patient was switched back to insulin when diagnosed with renal insufficiency.